Cancer immunotherapy has made remarkable progress in the past decade. Bispecific
antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody …

Immune checkpoint inhibitors have revolutionized the treatment landscape for a number of
cancers over the last few decades. Nevertheless, a majority of patients still do not benefit …

Simple Summary Survival after diagnosis of metastatic uveal melanoma has not significantly
improved over decades, most patients die within a year from diagnosis. Uveal melanoma is …

Simple Summary Although rare, uveal melanoma (UM) is the most common cancer that
develops inside adult eyes. The prognosis is poor, since 50% of patients will develop lethal …

Simple Summary Glycoprotein 100 (Gp-100) is a protein highly expressed in melanoma
tissue that has recently been effectively targeted by tebentafusp, a first-in-class bispecific …

Simple Summary Percutaneous hepatic perfusion (PHP) with melphalan is an innovative
technique that facilitates the delivery of high-dose chemotherapy to hepatic tumors while …

The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma
patients has been evolving recently. Due to a reduced immune function in elderly patients …

Uveal melanomas account for 3− 5% of all melanomas and, unlike their more common
cutaneous counterparts, have a low prevalence of targetable BRAF mutations and limited …

While the COVID-19 pandemic also affected the work of regulatory authorities, the US Food
and Drug Administration approved a total of 53 new drugs in 2020, one of the highest …

Simple Summary Immune checkpoint inhibitors (ICI) have failed to overcome the high
therapy resistance of Metastatic Uveal Melanoma (MUM) in contrast to the dramatic benefits …